FindTrial
Sign In

Gallium Ga 68 Gozetotide

OTHER18 trials

Sponsors

Jonsson Comprehensive Cancer Center, Mayo Clinic, Emory University, University of Washington, Fred Hutchinson Cancer Center

Conditions

Advanced Hepatocellular CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Biochemically Recurrent Prostate CarcinomaCastration-Resistant Prostate CarcinomaHepatocellular CarcinomaInvasive Breast Lobular CarcinomaMetastatic Breast Lobular CarcinomaMetastatic Castration-Resistant Prostate Carcinoma

Early Phase 1

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
CompletedNCT04310540
Mayo ClinicHepatocellular Carcinoma
Start: 2020-06-05End: 2023-11-02Updated: 2024-09-19
Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma
WithdrawnNCT05111314
Mayo ClinicHepatocellular Carcinoma
Start: 2022-02-11End: 2023-08-14Updated: 2023-11-07
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Active, not recruitingNCT05160597
Jonsson Comprehensive Cancer CenterProstate Carcinoma
Start: 2022-01-13End: 2027-01-07Target: 30Updated: 2026-02-12

Phase 1

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
TerminatedNCT04279561
Jonsson Comprehensive Cancer CenterCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVA Prostate Cancer AJCC v8 +2
Start: 2020-04-16End: 2022-09-15Updated: 2022-09-21
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
CompletedNCT04750473
Emory UniversityAnatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma +1
Start: 2021-07-16End: 2024-03-21Updated: 2025-01-17

Phase 2

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
CompletedNCT04762888
Mayo ClinicHepatocellular Carcinoma
Start: 2021-02-24End: 2025-06-26Updated: 2025-10-31
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
Active, not recruitingNCT04777071
University of WashingtonBiochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma +3
Start: 2021-05-17End: 2030-07-15Updated: 2026-01-09
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
TerminatedNCT04928820
Jonsson Comprehensive Cancer CenterBiochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma +3
Start: 2021-06-16End: 2022-10-18Updated: 2022-10-21
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
CompletedNCT05176223
Mayo ClinicAdvanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 +1
Start: 2022-01-30End: 2025-12-31Updated: 2026-02-05
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
RecruitingNCT06067269
Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8 +1
Start: 2024-03-28End: 2027-12-01Target: 95Updated: 2025-07-15
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
RecruitingNCT06145633
Fred Hutchinson Cancer CenterCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2024-09-18End: 2027-12-30Target: 15Updated: 2026-01-28
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RecruitingNCT06200103
Mayo ClinicCastration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2024-05-03End: 2029-12-31Target: 236Updated: 2025-09-11
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
RecruitingNCT06216249
Jonsson Comprehensive Cancer CenterProstate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Start: 2024-08-01End: 2028-12-31Target: 90Updated: 2026-03-10
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
RecruitingNCT06288113
Jonsson Comprehensive Cancer CenterCastration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2024-08-01End: 2028-01-27Target: 40Updated: 2026-03-13
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
RecruitingNCT07150715
Jonsson Comprehensive Cancer CenterOligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
Start: 2025-12-12End: 2031-10-31Target: 107Updated: 2025-12-17

Phase 3

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
CompletedNCT02940262
Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma, Recurrent Prostate Carcinoma
Start: 2016-09-15End: 2021-06-18Updated: 2021-07-02
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
CompletedNCT05547386
Mayo ClinicCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2022-05-09End: 2023-12-31Updated: 2025-07-18

Unknown Phase

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
CompletedNCT03368547
Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7 +1
Start: 2016-12-12End: 2021-06-18Updated: 2023-04-12

Related Papers

Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.
Cancer Research2026-04-03
VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.
Journal of Clinical Oncology2025-05-281 citations
Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial).
Journal of Clinical Oncology2025-05-28
A randomized phase 2 trial of flexible and extended dosing of <sup>177</sup> Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT): Trial in progress update.
Journal of Clinical Oncology2025-05-28
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
2024-10-184 citations
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
2024-07-085 citations
A randomized phase 2 trial in progress of flexible and extended dosing of <sup>177</sup>Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).
Journal of Clinical Oncology2024-06-011 citations
Pre-surgical <sup>68</sup>Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Journal of Clinical Oncology2024-02-01
Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study
EJNMMI Research2023-10-3010 citations
Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
2023-07-2115 citations
Pre-surgical <sup>68</sup>Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Journal of Clinical Oncology2023-06-01
Head-to-head comparison of <sup>68</sup>Ga-PSMA-11 PET with <sup>99</sup>mTc-MDP bone scan for detection of bone disease in patients with prostate cancer with biochemical progression during ADT: A single center prospective study.
Journal of Clinical Oncology2023-06-01
A Discordant Pattern of Uptake on 68Ga-PSMA PET/CT Versus 18F-Fluciclovine PET/CT in Radiation-Induced Hepatitis
Clinical Nuclear Medicine2023-01-147 citations
Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma
PLoS ONE2022-11-117 citations
A Tale of 3 Tracers
Clinical Nuclear Medicine2022-09-063 citations
Clinical impact of PSMA PET in patients with biochemically recurrent prostate cancer after locoregional definitive therapy.
Journal of Clinical Oncology2022-06-012 citations
Predictive value of extra-prostatic disease detection by pre-operative PSMA-PET for biochemical recurrence-free survival in patients treated with radical prostatectomy: Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Journal of Clinical Oncology2022-06-011 citations
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
PubMed2022-02-019 citations
Head-to-Head Comparison of<sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Journal of Nuclear Medicine2021-10-14122 citations
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Journal of Nuclear Medicine2021-10-0730 citations

16 more papers not shown